Loading clinical trials...
Loading clinical trials...
A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared With Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C
The purpose of this study is to compare the effectiveness of BMS-790052 (Daclatasvir) and Telaprevir when given in combination with Peginterferon alfa-2a and Ribavirin in genotype 1b patients
Allocation: Randomized Stratified
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
The Kirklin Clinic
Birmingham, Alabama, United States
Mayo Clinic Arizona
Phoenix, Arizona, United States
Va Long Beach Healthcare System
Long Beach, California, United States
Medical Associates Research Group
San Diego, California, United States
Yale University School Of Medicine
New Haven, Connecticut, United States
Orlando Immunology Center
Orlando, Florida, United States
Atlanta Medical Center
Atlanta, Georgia, United States
Gastrointestinal Specialists Of Georgia
Marietta, Georgia, United States
Northwestern University
Chicago, Illinois, United States
Rush University Medical Center
Chicago, Illinois, United States
Start Date
January 1, 2012
Primary Completion Date
December 1, 2013
Completion Date
March 1, 2014
Last Updated
June 3, 2016
605
ACTUAL participants
Daclatasvir
DRUG
Telaprevir
DRUG
Peginterferon alfa-2a
DRUG
Ribavirin
DRUG
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions